Overview
Actively managed equity portfolio investing worldwide in companies from the health transformation sector.
Efficient means of exploiting the potential of companies operating in the health Transformation area.
Specialised sector analysts seek out the attractive stocks in the Health Transformation area.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
This fund promotes environmental, social and corporate governance characteristics. The research and portfolio construction processes incorporate ESG risk integration and screening and comply with 麻豆社 Asset Management Sustainability exclusion policy. For more information on Sustainability at 麻豆社, please refer to www.ubs.com/am-si-commitment.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
The fund is pairing CIO identified investment themes with the stock selection and portfolio construction expertise of 麻豆社 Asset Management.
The fund taps into the knowledge of proven sector specialists.
麻豆社’s proprietary fundamental valuation approach allows consistent identification of the most attractive global health transformation companies.
Investors benefit from a global investment platform of 麻豆社 Asset Management.
Risks
Features
| Product category |
麻豆社 Equity Funds 麻豆社 Sector Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
麻豆社 Asset Management (Americas) LLC, New York
|
| Fund management |
麻豆社 Asset Management (Europe) S.A., Luxembourg
|
| Custodian bank |
麻豆社 Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
麻豆社 Fund Management (Switzerland) AG
|
| Day of inception |
November 24, 2021
|
| Currency of account |
USD
|
| Currency of unit class |
CHF
|
| Close of financial year |
November 30
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.05% p.a.
|
| Management fee |
0.77% p.a.
|
| Total expense ratio (TER) |
1.04% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI World Health Care (net div. reinv.)
|
| Securities no. |
114551785
|
| ISIN |
LU2402148659
|
| Bloomberg Ticker |
UBHCUHQ LX
|
Performance and Prices
Percentage growth
as of May 29, 2026| CHF(%) | EUR(%) | USD(%) | |
| YTD | -0.31 | 1.73 | 1.08 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 15.09 | 16.08 | 31.65 |
| 3Y | |||
| 5Y | |||
| ø p.a.5Y | 3.24 | 6.30 | 8.60 |
Current data
| Net asset value | 29.05.2026 | CHF 106.52 |
| High - last 12 months | 27.02.2026 | CHF 111.92 |
| Low - last 12 months | 08.08.2025 | CHF 88.59 |
| Assets of the unit class in mn | 29.05.2026 | CHF 24.87 |
| Total product assets in mn | 29.05.2026 | CHF 209.44 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 30.04.2026 | 14.01% | 14.05% |
| Sharpe Ratio | 30.04.2026 | 0.31 | n.a. |
| Risk Free Rate | 30.04.2026 | 0.40% | 0.41% |
Structures
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|||||
| Prospectus |
|
|
||||
| Key Information Document |
|
|
|
|
||
| Past performance |
|
|
|
|
||
| Previous performance scenario |
|
|
|
|
||
| Statutes / Management regulations |
|
|
||||
| ESG Disclosure |
|
|
|
|
|
|
| SFDR Pre-Contractual Annex |
|
|
Document type
|
Document Language
|
||
| Annual report |
|
|
|
| SFDR Periodic Report Annex |
|
||
| Semi-annual report |
|
|
|
|
Document type
|
Document Language
|
|||
| Tax list |
|
|
|
|